• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康的微生物群是否是新冠病毒肺炎死亡率较低的原因?

Is a healthy microbiome responsible for lower mortality in COVID-19?

作者信息

Janda Lubomír, Mihalčin Matúš, Šťastná Michaela

机构信息

Clinical Immunology and Immunology of Infectious Diseases, Veterinary Research Institute, Brno, Hudcova 70, 621 00 Brno, Czech Republic.

Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.

出版信息

Biologia (Bratisl). 2021;76(2):819-829. doi: 10.2478/s11756-020-00614-8. Epub 2020 Oct 15.

DOI:10.2478/s11756-020-00614-8
PMID:33078028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7557238/
Abstract

The novel severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic with significant case fatality ratio (CFR) worldwide. Although SARS-CoV-2 primarily causes respiratory infection by binding to ACE2 receptors present on alveolar epithelial cells, studies have been published linking the disease to the small intestine enterocytes and its microbiome. Dysbiosis of microbiome, mainly intestinal and lung, can affect the course of the disease. Environmental factors, such as reduced intake of commensal bacteria from the environment or their products in the diet, play an important role in microbiome formation, which can significantly affect the immune response. In elderly, obese or chronically ill people, the microbiota is often damaged. Therefore, we speculate that a good microbiome may be one of the factors responsible for lower CFR from the coronavirus disease 2019 (COVID-19). An approach using tailored nutrition and supplements known to improve the intestinal microbiota and its immune function might help minimize the impact of the disease at least on people at higher risk from coronavirus.

摘要

新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是全球范围内正在流行且病死率较高的疫情的病原体。虽然SARS-CoV-2主要通过与肺泡上皮细胞上的血管紧张素转换酶2(ACE2)受体结合引起呼吸道感染,但已有研究发表,将该疾病与小肠肠上皮细胞及其微生物群联系起来。微生物群的失调,主要是肠道和肺部的,会影响疾病的进程。环境因素,如从环境中摄入共生细菌或其饮食中的产物减少,在微生物群的形成中起重要作用,这会显著影响免疫反应。在老年人、肥胖者或慢性病患者中,微生物群往往受损。因此,我们推测良好的微生物群可能是导致2019冠状病毒病(COVID-19)病死率较低的因素之一。一种使用已知可改善肠道微生物群及其免疫功能的定制营养和补充剂的方法,可能有助于至少将该疾病对冠状病毒高风险人群的影响降至最低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/d69178f73c6e/11756_2020_614_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/adc235f3034d/11756_2020_614_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/5fbe4826b545/11756_2020_614_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/b8a6663b7f69/11756_2020_614_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/d69178f73c6e/11756_2020_614_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/adc235f3034d/11756_2020_614_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/5fbe4826b545/11756_2020_614_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/b8a6663b7f69/11756_2020_614_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7213/7557238/d69178f73c6e/11756_2020_614_Fig4_HTML.jpg

相似文献

1
Is a healthy microbiome responsible for lower mortality in COVID-19?健康的微生物群是否是新冠病毒肺炎死亡率较低的原因?
Biologia (Bratisl). 2021;76(2):819-829. doi: 10.2478/s11756-020-00614-8. Epub 2020 Oct 15.
2
Gut microbiota and Covid-19- possible link and implications.肠道微生物群与新冠病毒(COVID-19):可能的联系及影响。
Virus Res. 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018. Epub 2020 May 13.
3
Microbiota and Its Impact on the Immune System in COVID-19-A Narrative Review.微生物群及其对COVID-19免疫系统的影响——一篇叙述性综述
J Clin Med. 2021 Sep 30;10(19):4537. doi: 10.3390/jcm10194537.
4
Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known?新型冠状病毒感染中的肠道微生物群:已知什么?
Adv Exp Med Biol. 2021;1327:93-106. doi: 10.1007/978-3-030-71697-4_7.
5
Potential Associations Between Microbiome and COVID-19.微生物群与2019冠状病毒病之间的潜在关联。
Front Med (Lausanne). 2021 Dec 22;8:785496. doi: 10.3389/fmed.2021.785496. eCollection 2021.
6
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome.SARS-CoV-2 感染和病毒载量与上呼吸道微生物组有关。
J Allergy Clin Immunol. 2021 Apr;147(4):1226-1233.e2. doi: 10.1016/j.jaci.2021.02.001. Epub 2021 Feb 9.
7
The Role of Bacterial and Fungal Human Respiratory Microbiota in COVID-19 Patients.细菌和真菌在人类呼吸道微生物群在 COVID-19 患者中的作用。
Biomed Res Int. 2021 Feb 23;2021:6670798. doi: 10.1155/2021/6670798. eCollection 2021.
8
Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases.微生物组的影响:针对病毒病不断发展群体免疫的范例。
Viruses. 2020 Oct 10;12(10):1150. doi: 10.3390/v12101150.
9
Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to ?新冠病毒阳性患者鼻咽微生物组特征:我们能明确其作用吗?
Front Cell Infect Microbiol. 2021 Feb 15;11:625581. doi: 10.3389/fcimb.2021.625581. eCollection 2021.
10
Metagenomic analysis of RNA sequencing data reveals SARS-CoV-2-mediated progressive dysbiosis of upper respiratory tract microbiota.宏基因组分析 RNA 测序数据揭示了 SARS-CoV-2 介导的上呼吸道微生物组进行性失调。
Biomed J. 2021 Aug;44(4):504-507. doi: 10.1016/j.bj.2021.02.008. Epub 2021 Feb 27.

引用本文的文献

1
Gut Microbiota and COVID-19: Unraveling the Gut-Lung Axis and Immunomodulatory Therapies.肠道微生物群与2019冠状病毒病:揭示肠-肺轴与免疫调节疗法
ACS Infect Dis. 2025 Jul 11;11(7):1844-1853. doi: 10.1021/acsinfecdis.5c00250. Epub 2025 Jun 5.
2
Bifidobacterium Against COVID-19: A Mother and Her Newborn's Gut Microbiome.双歧杆菌对抗新冠病毒:一位母亲及其新生儿的肠道微生物群
Cureus. 2024 May 10;16(5):e60038. doi: 10.7759/cureus.60038. eCollection 2024 May.
3
A prospective observational study to correlate lung ultrasound with clinical severity and prognosis score in patients with primary pulmonary pathology on invasive ventilatory support.

本文引用的文献

1
Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study.实验室确诊的季节性冠状病毒(HCoV-NL63、HCoV-OC43和HCoV-229E)的季节性与免疫力:流感监测队列研究结果
Wellcome Open Res. 2020 Dec 10;5:52. doi: 10.12688/wellcomeopenres.15812.2. eCollection 2020.
2
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.无症状或轻症 COVID-19 康复者体内具有强大的 T 细胞免疫。
Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14.
3
Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea.
一项前瞻性观察性研究,旨在探讨接受有创通气支持的原发性肺部疾病患者肺超声与临床严重程度及预后评分之间的相关性。
Int J Crit Illn Inj Sci. 2023 Oct-Dec;13(4):151-158. doi: 10.4103/ijciis.ijciis_31_23. Epub 2023 Dec 26.
4
Downregulation of ACE, AGTR1, and ACE2 genes mediating SARS-CoV-2 pathogenesis by gut microbiota members and their postbiotics on Caco-2 cells.肠道微生物群及其代谢产物对 Caco-2 细胞介导 SARS-CoV-2 发病机制的 ACE、AGTR1 和 ACE2 基因的下调作用。
Microb Pathog. 2022 Dec;173(Pt A):105798. doi: 10.1016/j.micpath.2022.105798. Epub 2022 Sep 26.
5
Lost microbes of COVID-19: , depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.新冠病毒丢失的微生物:与 SARS-CoV-2 感染严重程度相关的、耗尽和减少的微生物组多样性。
BMJ Open Gastroenterol. 2022 Apr;9(1). doi: 10.1136/bmjgast-2022-000871.
6
Altered Ecology of the Respiratory Tract Microbiome and Nosocomial Pneumonia.呼吸道微生物群生态变化与医院获得性肺炎
Front Microbiol. 2022 Feb 10;12:709421. doi: 10.3389/fmicb.2021.709421. eCollection 2021.
7
Association between severity of COVID-19 symptoms and habitual food intake in adult outpatients.成年门诊患者中新冠病毒病症状严重程度与习惯性食物摄入量之间的关联
BMJ Nutr Prev Health. 2021 Nov 12;4(2):469-478. doi: 10.1136/bmjnph-2021-000348. eCollection 2021.
8
SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts.SARS-CoV-2 感染减少了人类鼻咽共生微生物组,并包含了病原体。
Sci Rep. 2021 Dec 15;11(1):24042. doi: 10.1038/s41598-021-03245-4.
9
Impact of COVID-19 on the Intestinal Microbiome.新冠疫情对肠道微生物组的影响。
Curr Nutr Rep. 2021 Dec;10(4):300-306. doi: 10.1007/s13668-021-00375-z. Epub 2021 Nov 23.
10
Does Fecal-Oral Transmission of SARS-CoV-2 Due to Low Sanitation Conditions Contribute to Low Mortality Rates From COVID-19.由于卫生条件差导致的新冠病毒粪口传播是否会导致新冠肺炎死亡率较低?
Cureus. 2021 Oct 7;13(10):e18557. doi: 10.7759/cureus.18557. eCollection 2021 Oct.
韩国社区治疗中心中无症状和有症状的 SARS-CoV-2 感染患者的临床病程和分子病毒脱落情况。
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452. doi: 10.1001/jamainternmed.2020.3862.
4
Drugs against SARS-CoV-2: What do we know about their mode of action?抗 SARS-CoV-2 药物:它们的作用机制我们了解多少?
Rev Med Virol. 2020 Nov;30(6):1-10. doi: 10.1002/rmv.2143. Epub 2020 Aug 11.
5
Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting.SARS-CoV-2 突变对基因组 RNA 结构和宿主 microRNA 靶向的影响。
Int J Mol Sci. 2020 Jul 7;21(13):4807. doi: 10.3390/ijms21134807.
6
T-UCRs with digestive and respiratory diseases.具有消化和呼吸系统疾病的 T-UCRs。
Bioorg Med Chem Lett. 2020 Aug 15;30(16):127306. doi: 10.1016/j.bmcl.2020.127306. Epub 2020 Jun 2.
7
Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.肠道菌群作为对抗新冠病毒感染的潜在策略
Front Microbiol. 2020 Jun 9;11:1388. doi: 10.3389/fmicb.2020.01388. eCollection 2020.
8
A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.一种 SARS-CoV-2 病毒 RNA 复制机器的结构视图:RNA 合成、校对和最终加帽。
Cells. 2020 May 20;9(5):1267. doi: 10.3390/cells9051267.
9
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.针对 SARS-CoV-2 的免疫反应和 COVID-19 中免疫病理变化的机制。
Allergy. 2020 Jul;75(7):1564-1581. doi: 10.1111/all.14364.
10
Beware: Gastrointestinal symptoms can be a manifestation of COVID-19.注意:胃肠道症状可能是新冠病毒病的一种表现。
Rev Gastroenterol Mex (Engl Ed). 2020 Jul-Sep;85(3):282-287. doi: 10.1016/j.rgmx.2020.04.001. Epub 2020 Apr 15.